A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma - Concepedia

Concepedia

Publication | Open Access

A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma

DOI Full Paper Access

95

Citations

23

References

2012

Year

Andrea Wang‐Gillam, Stacey M. Plambeck-Suess, Peter S. Goedegebuure, Peter O. Simon, Jonathan B. Mitchem, John R. Hornick, Steven Sorscher, Joel Picus, Rama Suresh, A. Craig Lockhart,

Investigational New Drugs

Pancreatic CancerFront-line TherapyGastrointestinal OncologyMedicinePathologyCancer TreatmentOncologyRadiation OncologyAdvanced Pancreatic Adenocarcinoma

References

	Year	Citations

Page 1

Page 1